x NoneEntity Type
0001557746
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Aclaris Therapeutics, Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Aclaris Therapeutics, Inc. 
Street Address 1Street Address 2
 640 LEE ROAD, SUITE 200 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 WAYNE PENNSYLVANIA 19087 484-324-7933 



3. Related Persons
Last NameFirst NameMiddle Name
WalkerNeal
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
RuffoFrank
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
GordonDavid
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
Ali-JacksonKamil
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
MolineauxChristopher
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
MehraAnand
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HumphriesWilliam
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
PowellAndrew
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
SchiffAndrew
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
ReasonsBryan
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
GowenMaxine
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
MilanoVincent
Street Address 1Street Address 2
c/o Aclaris Therapeutics, Inc.640 Lee Road, Suite 200
CityState/Province/CountryZIP/Postal Code
WaynePENNSYLVANIA19087
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-03-30 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities x Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 11440000 USD o Indefinite
Total Amount Sold $ 11000000 USD 
Total Remaining to be Sold $ 440000 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Aclaris Therapeutics Charts.
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Aclaris Therapeutics Charts.

Aclaris Therapeutics, Inc. News

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
Tuesday 30 April 2024 (4 days ago) • GlobeNewswire Inc.
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Tuesday 23 April 2024 (2 weeks ago) • PR Newswire (US)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 6 February 2024 (3 months ago) • Edgar (US Regulatory)

More Aclaris Therapeutics, Inc. News Articles